IN8bio reported improved financial results for Q3 2025, with a reduced net loss and lower operating expenses compared to the prior year. The company also highlighted advancements in its preclinical and clinical pipeline, including new data for INB-619 and expansion of the INB-100 trial.
Net loss decreased to $3.9 million in Q3 2025 from $7.1 million in Q3 2024.
positiveNet loss per share improved to ($0.85) in Q3 2025 from ($4.49) in Q3 2024.
positiveResearch and Development expenses decreased to $2.1 million in Q3 2025 from $3.3 million in Q3 2024.
positiveGeneral and administrative expenses decreased to $1.9 million in Q3 2025 from $2.7 million in Q3 2024.
positivePresented compelling preclinical data on INB-619 demonstrating equivalent potency to FDA-approved commercial products with minimal adverse cytokine release.
positiveExpanded Phase 1 INB-100 trial to The Ohio State University to accelerate patient enrollment.
positiveThe company reported a net loss of $3.9 million for the three months ended September 30, 2025.
negativeTotal operating expenses were $4.0 million for Q3 2025, a decrease from $7.1 million in Q3 2024, but still represent significant ongoing costs.
attentionThe company's accumulated deficit stands at $136.2 million as of September 30, 2025.
negativeCash balance of $10.7 million as of September 30, 2025, may require additional capital raises to fund ongoing operations and development.
attentionMargin metrics will be available once backend extracts data from insights_json
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Our focus on the novel biology of γδ T cells underscores our advancements along with the strength and versatility of our DeltEx™ platform.
This quarter, we expanded our INB-100 clinical operations to additional sites to accelerate enrollment, and we reported compelling preclinical data at the 2025 ACR Convergence Meeting.
Our INB-619 program is a novel and differentiated program in a sea of CD3-based TCE’s that have yet to achieve immune reset in the autoimmune disease setting.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.